“Close the Care Gap” – World Cancer Day 2024
Since the year 2000, World Cancer Day has been observed globally on February 4th, marking a positive movement that unites people worldwide under a single voice to confront one of the most significant medical challenges in history.1
Led by the Union for International Cancer Control (UICC), World Cancer Day not only raises awareness but also improves education, influences government actions, while collectively working together to reimagine a world where loss and deaths to cancer are more preventable.1
This year’s theme, “Close the Care Gap,” acknowledges that despite advancements in cancer treatments, obstacles persist for many seeking care. Factors such as income, education, geographical location, and discrimination can create barriers when accessing essential care services.1
The formulation and advancement of cancer drugs encompass a diverse array of options, including essential components for small molecule drugs, adjuvants to enhance vaccine therapies and the innovation seen in developing personalised medicines.
Explore our commitments and how we are helping!
As innovation continues in the development of drugs to treat and cure cancer, novel excipients and adjuvants play a crucial role. “Modern vaccine development is having a golden period, with a variety of novel subunit technologies being introduced into clinical development in recent years” states Dr. Dennis Christensen, Head of Adjuvant Systems Research & Development, Croda Pharma.2 While COVID-19 brought the world to a halt, the rapid drug developments in response led to several novel vaccine platforms, ultimately opening the door for more innovation, giving vaccine development a tremendous boost.2
Novel adjuvants, such as CAF®09B for example, have been seen in studies for personalised medicines such as cancer immunotherapy as most neoantigens arise from unique mutations and are not shared between individual patience, thus, neoantigen-directed immunotherapy needs to be personalised.3 The referenced study by EVAXION used the proprietary AI-Immunology™ platform,4 PIONEER, to identify a neo-antigen vaccine, formulated with the novel liposomal adjuvant CAF®09B to potentiate the immune response, tailored to the individual patient3 diagnosed with metastatic melanoma.4 The study utilised artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections.4
Featured
CAF09b®
A novel liposomal adjuvant used in cancer immunotherapy trials, CAF09b has the capacity to facilitate the production of CD8+ T-cells.
As the development for innovative cancer therapies continue, we are committed to support innovation through providing access to novel adjuvants and increase supply chain security. CAF®09B is just one example of a novel adjuvant supporting the limited options for metastatic diseases, addressing the need for new therapies.5
We are proud to continue supporting the development of cancer treatments, and on this World Cancer Day, recognise the importance of innovation and science to cure and treat those diagnosed. Together, we stand in support to “Close the Care Gap.”
Explore recent blogs:
Lipid Leaders: Söhnke Voss
In this Lipid Leaders interview, we speak to Söhnke Voss, PhD. Söhnke is a lipids expert with over 25 years’ experience in the pharmaceutical industry. Keep reading to learn more about lipids and the...
Read more
Croda Pharma wins ‘Best Production/Process Development’ Award at the 17th annual Vaccine Industry Excellence awards
Croda Pharma has been awarded winner of a prestigious award for its process development for innovative ingredients, including its production of sustainably sourced Squalene to replace shark-derived...
Read more
Partnership agreement between Croda and AAHI to drive innovation in vaccine development
19 March 2024: Croda International Plc (Croda) and The Access to Advanced Health Institute (AAHI) are pleased to announce today the signing of a partnership agreement around innovation and development...
Read more
Croda Foundation announces it has sustainably improved the lives of 22.8 million people – exceeding its 2030 target.
Croda Foundation announces it has sustainably improved the lives of 22.8 million people –exceeding its 2030 target.
Read more2, Dennis Christensen (24 October 2023). “Head-to-Head Comparison of Novel Vaccine Technologies Comes with a Minefield of Challenges.” Available at: https://doi.org/10.3390/pharmaceutics16010012 (Accessed: 2 Feb 2024)
3, Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) (NeoPepVac). Available at: https://www.clinicaltrials.gov/study/NCT03715985 (Accessed: 2 Feb 2024)
4, Evaxion Share Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak. Available at: https://investors.evaxion-biotech.com/news-releases/news-release-details/evaxion-shares-latest-evx-01-phase-2-clinical-data-webinar-key (Accessed: 2 Feb 2024)
5, Promising new results for metastatic prostate cancer vaccine. Available at: https://www.crodapharma.com/en-gb/news-and-blog/promising-new-results-for-metastatic-prostate-cancer-vaccine (Accessed: 2 Feb 2024)